ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
The Boosting Bispecific Antibody Therapeutics Market: Market Size Exceeded USD3.5 Billion by 2021
March 30, 2022So far this year, there has been good news on the bispecific antibody therapeutics market. -
Janssen’s Phase 1 Results for Teclistamab Suggest Deep, Durable Responses
May 28, 2021Subcutaneous administration of BCMAxCD3 T-cell redirecting bispecific antibody demonstrated clinical activity and a manageable safety profile according to new data at ASCO. -
SpringWorks, Janssen to Evaluate Nirogacestat with Teclistamab for Multiple Myeloma
September 21, 2020SpringWorks Therapeutics has entered into a clinical collaboration and supply agreement with Janssen Biotech to evaluate SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody ... -
SpringWorks Therapeutics in pact with Janssen to assess Nirogacestat with Teclistamab in patients with relapsed or refractory multiple myeloma
September 15, 2020Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities.
Pharma Sources Insight July 2025
